Close Menu

A*Star

The kit was jointly developed by Singapore's Agency for Science, Technology, and Research, Tan Tock Seng Hospital, and MiRxes.

The assay underwent clinical validation at three centers in Singapore and 5,248 patients were ultimately screened using the test.

News items for the in vitro diagnostics industry for the week of Oct. 26, 2020.

The assay is designed to detect immunoglobulin G and M antibodies against SARS-CoV-2 in human blood, plasma, and serum, with results provided in 15 minutes.

The test is designed to detect circulating neutralizing antibodies against the virus without the need for live biological materials or biosafety containment.

A*STAR and Tan Tock Seng Hospital developed the test, which is the first diagnostic to be deployed in the country's hospitals since the outbreak began in December.

The IMCB-A!maginostic Joint Lab of Excellence will provide AI- and machine learning-based solutions to support computational digital and multiplex pathology.

The company's goal is to serve what it sees as a massive but underaddressed target group: Asian women.

The company will work with the Genome Institute of Singapore to create a test for breast cancer recurrence prediction using its circulating tumor cell platform.

One BioMed was spun out of Singapore's Agency for Science, Technology, and Research to  develop a point-of-care diagnostic platform for infectious disease.

Pages